Task: Translation
Input (Czech): Nestechiometrická hydratovaná krystalická forma 6-hydroxy-3-[4-/2-(piperidin-1-yl)ethoxy/fenoxy]-2-(4-methoxyfenyl)benzo[b]thiofenhydrochloridu (neboli F-I), farmaceutický prostredek obsahující F-I afarmaceutický nosic, redidlo nebo excipient, zpusob prípravy F-I krystalizací z tetrahydrofuranu. F-I pro použití pri inhibici chorobných stavu spojených s estrogenní deprivací, kardiovaskulárních onemocneních, hyperlipidémie a osteoporózou; a inhibici jiných patologických stavu, jako jsou endometrióza, fibróza delohy, na estrogenu dependentní zhoubné nádory (vcetne karcinomu prsu a delohy), karcinom prostaty, benigní hyperplazie prostaty, onemocnení CNS vcetne Alzheimerovy choroby, prevence karcinomu prsu a up-regulace ChAT.
Output (English): The present invention relates to a novel non-stoichiometric crystalline hydrate of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]-phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride (or the F-I compound), a pharmaceutical composition containing the F-I compound and a pharmaceutical composition containing the F-I compound and a pharmaceutically acceptable carrier, solvent or excipient, process for preparing the F-I compound by crystallization from tetrahydrofuran. The invention also relates to uses for same, including inhibition of disease states associated with estrogen deprivation including cardiovascular disease, hyperlipidemia, and osteoporosis; and inhibition of other pathological conditions such as endometriosis, uterine fibrosis, estrogen-dependent cancer (including breast and uterine cancer), prostate cancer, benign prostatic hyperplasia, CNS disorders including Alzheimer's disease, prevention of breast cancer, and up-regulating ChAT.